$1.10 Million in Sales Expected for AcelRx Pharmaceuticals Inc (ACRX) This Quarter

Share on StockTwits

Wall Street brokerages expect AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) to post $1.10 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for AcelRx Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $800,000.00 and the highest estimate coming in at $1.40 million. AcelRx Pharmaceuticals reported sales of $1.49 million during the same quarter last year, which indicates a negative year over year growth rate of 26.2%. The firm is expected to report its next earnings results on Thursday, November 8th.

According to Zacks, analysts expect that AcelRx Pharmaceuticals will report full year sales of $4.83 million for the current fiscal year, with estimates ranging from $1.00 million to $11.00 million. For the next year, analysts expect that the company will post sales of $19.90 million per share, with estimates ranging from $11.00 million to $30.50 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover AcelRx Pharmaceuticals.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its quarterly earnings data on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The company had revenue of $0.82 million during the quarter, compared to the consensus estimate of $0.93 million.

Several brokerages recently issued reports on ACRX. Cantor Fitzgerald reissued an “overweight” rating on shares of AcelRx Pharmaceuticals in a research note on Thursday, June 14th. Zacks Investment Research cut AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, June 26th. Oppenheimer reaffirmed a “hold” rating on shares of AcelRx Pharmaceuticals in a research report on Friday, August 3rd. ValuEngine raised AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 1st. Finally, HC Wainwright reaffirmed a “buy” rating on shares of AcelRx Pharmaceuticals in a research report on Tuesday, August 7th. Five analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. AcelRx Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $5.21.

In other AcelRx Pharmaceuticals news, CEO Vincent J. Angotti acquired 10,000 shares of the firm’s stock in a transaction dated Tuesday, August 7th. The stock was purchased at an average price of $2.90 per share, for a total transaction of $29,000.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Pamela P. Palmer acquired 37,000 shares of the firm’s stock in a transaction dated Monday, August 6th. The shares were acquired at an average price of $2.75 per share, with a total value of $101,750.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 57,300 shares of company stock worth $159,552 in the last ninety days. Insiders own 25.50% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of ACRX. Northern Trust Corp lifted its holdings in shares of AcelRx Pharmaceuticals by 60.8% during the 1st quarter. Northern Trust Corp now owns 91,481 shares of the specialty pharmaceutical company’s stock valued at $192,000 after purchasing an additional 34,584 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in shares of AcelRx Pharmaceuticals during the 1st quarter valued at $113,000. Lincoln Capital Corp purchased a new stake in shares of AcelRx Pharmaceuticals during the 2nd quarter valued at $116,000. Granite Investment Partners LLC purchased a new stake in shares of AcelRx Pharmaceuticals during the 2nd quarter valued at $182,000. Finally, BlackRock Inc. lifted its holdings in shares of AcelRx Pharmaceuticals by 2.7% during the 2nd quarter. BlackRock Inc. now owns 673,115 shares of the specialty pharmaceutical company’s stock valued at $2,271,000 after purchasing an additional 17,737 shares during the last quarter. Hedge funds and other institutional investors own 8.59% of the company’s stock.

NASDAQ:ACRX traded up $0.05 during midday trading on Wednesday, hitting $3.25. The stock had a trading volume of 191,720 shares, compared to its average volume of 418,834. AcelRx Pharmaceuticals has a one year low of $1.55 and a one year high of $5.75. The stock has a market cap of $193.92 million, a P/E ratio of -2.95 and a beta of 2.09. The company has a quick ratio of 3.96, a current ratio of 4.01 and a debt-to-equity ratio of -0.15.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Featured Article: What does EPS mean?

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply